Literature DB >> 15059948

Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.

Bronwyn D Hegarty1, Stuart M Furler, Nicholas D Oakes, Edward W Kraegen, Gregory J Cooney.   

Abstract

Agonists of peroxisome proliferator-activated receptors (PPARs) have emerged as important pharmacological agents for improving insulin action. A major mechanism of action of PPAR agonists is thought to involve the alteration of the tissue distribution of nonesterified fatty acid (NEFA) uptake and utilization. To test this hypothesis directly, we examined the effect of the novel PPARalpha/gamma agonist tesaglitazar on whole-body insulin sensitivity and NEFA clearance into epididymal white adipose tissue (WAT), red gastrocnemius muscle, and liver in rats with dietary-induced insulin resistance. Wistar rats were fed a high-fat diet (59% of calories as fat) for 3 wk with or without treatment with tesaglitazar (1 micromol.kg(-1).d(-1), 7 d). NEFA clearance was measured using the partially metabolizable NEFA tracer, (3)H-R-bromopalmitate, administered under conditions of basal or elevated NEFA availability. Tesaglitazar improved the insulin sensitivity of high-fat-fed rats, indicated by an increase in the glucose infusion rate during hyperinsulinemic-euglycemic clamp (P < 0.01). This improvement in insulin action was associated with decreased diglyceride (P < 0.05) and long chain acyl coenzyme A (P < 0.05) in skeletal muscle. NEFA clearance into WAT of high-fat-fed rats was increased 52% by tesaglitazar under basal conditions (P < 0.001). In addition the PPARalpha/gamma agonist moderately increased hepatic and muscle NEFA utilization and reduced hepatic triglyceride accumulation (P < 0.05). This study shows that tesaglitazar is an effective insulin-sensitizing agent in a mild dietary model of insulin resistance. Furthermore, we provide the first direct in vivo evidence that an agonist of both PPARalpha and PPARgamma increases the ability of WAT, liver, and skeletal muscle to use fatty acids in association with its beneficial effects on insulin action in this model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059948     DOI: 10.1210/en.2004-0260

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  13 in total

1.  Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps.

Authors:  Pooja Singal; Ranganath Muniyappa; Robin Chisholm; Gail Hall; Hui Chen; Michael J Quon; Kieren J Mather
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-17       Impact factor: 4.310

2.  Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?

Authors:  S Mittra; G Sangle; R Tandon; S Sharma; S Roy; V Khanna; A Gupta; J Sattigeri; L Sharma; P Priyadarsiny; S K Khattar; R S Bora; K S Saini; V S Bansal
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

3.  Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.

Authors:  Yang Hu; Ying Chen; Lexi Ding; Xuemin He; Yusuke Takahashi; Yang Gao; Wei Shen; Rui Cheng; Qian Chen; Xiaoping Qi; Michael E Boulton; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-03       Impact factor: 11.205

4.  Long chain fatty acid uptake in vivo: comparison of [125I]-BMIPP and [3H]-bromopalmitate.

Authors:  Jane Shearer; Kimberly R Coenen; R Richard Pencek; Larry L Swift; David H Wasserman; Jeffrey N Rottman
Journal:  Lipids       Date:  2008-05-15       Impact factor: 1.880

5.  Crocetin improves the insulin resistance induced by high-fat diet in rats.

Authors:  L Sheng; Z Qian; Y Shi; L Yang; L Xi; B Zhao; X Xu; H Ji
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

Review 6.  Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.

Authors:  Sonia Villapol
Journal:  Cell Mol Neurobiol       Date:  2017-10-03       Impact factor: 5.046

Review 7.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

8.  The E3 ligase MARCH5 is a PPARγ target gene that regulates mitochondria and metabolism in adipocytes.

Authors:  Simon T Bond; Sarah C Moody; Yingying Liu; Mete Civelek; Claudio J Villanueva; Paul Gregorevic; Bronwyn A Kingwell; Andrea L Hevener; Aldons J Lusis; Darren C Henstridge; Anna C Calkin; Brian G Drew
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-04       Impact factor: 5.900

Review 9.  The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.

Authors:  Charikleia Kalliora; Konstantinos Drosatos
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

10.  Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.

Authors:  Eileen R Blasi; Jonathan Heyen; Michelle Hemkens; Aileen McHarg; Carolyn M Ecelbarger; Swasti Tiwari
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.